Falls Church, VA · Founded 2021 · Privately Held (backing)
Developer an intestinal microsomal triglyceride transfer protein inhibitor designed to treat the metabolic side effects of antipsychotic drugs. Response Pharmaceuticals is based in Falls Church, VA and was founded in 2021. It was valued at $30 million at its early-stage round in Nov 2025, the last priced event on record. It has raised $16.9 million across 2 recorded rounds; the latest was a $3.9 million debt round in Jun 2024.
PMV mark · valuation
$30.0M
Oct 2026
Priced at
its early-stage round
Nov 2025
Total raised
$16.9M
Last round
Debt
Jun 2024
No prints on record
No secondary trades in Response Pharmaceuticals shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Response Pharmaceuticals with a free account
·Watch Response Pharmaceuticals: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Response Pharmaceuticals stock.
